{"id":"NCT03052322","sponsor":"Fresenius Kabi SwissBioSim GmbH","briefTitle":"MSB11022 in Moderate to Severe Rheumatoid Arthritis","officialTitle":"A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira® in Patients With Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-31","primaryCompletion":"2018-05-28","completion":"2018-08-27","firstPosted":"2017-02-14","resultsPosted":"2019-04-23","lastUpdate":"2019-12-20"},"enrollment":288,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"MSB11022","otherNames":["Adalimumab"]},{"type":"DRUG","name":"EU-Humira","otherNames":[]}],"arms":[{"label":"MSB11022","type":"EXPERIMENTAL"},{"label":"EU-Humira","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult participants with rheumatoid arthritis (RA).","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)","timeFrame":"Up to Week 52","effectByArm":[{"arm":"MSB11022","deltaMin":4.2,"sd":null},{"arm":"EU-Humira","deltaMin":5.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":46,"countries":["Bulgaria","Czechia","Germany","Hungary","Poland","United Kingdom"]},"refs":{"pmids":["33263165"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":143},"commonTop":["Nasopharyngitis","Injection site erythema","Injection site pain","Erythema","Injection site pruritus"]}}